2019 Q4 Form 10-Q Financial Statement
#000156459021005944 Filed on February 16, 2021
Income Statement
| Concept | 2019 Q4 | 2019 Q3 |
|---|---|---|
| Revenue | $12.81M | $11.65M |
| YoY Change | -9.97% | 14.16% |
| Cost Of Revenue | $5.097M | $4.344M |
| YoY Change | -44.43% | 10.9% |
| Gross Profit | $7.708M | $7.308M |
| YoY Change | -41.54% | -10.17% |
| Gross Profit Margin | 60.2% | 62.72% |
| Selling, General & Admin | $6.083M | $6.090M |
| YoY Change | -46.47% | -15.43% |
| % of Gross Profit | 78.92% | 83.33% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $350.0K | $335.0K |
| YoY Change | -49.2% | -19.86% |
| % of Gross Profit | 4.54% | 4.58% |
| Operating Expenses | $7.427M | $7.528M |
| YoY Change | -47.12% | -15.35% |
| Operating Profit | $281.0K | -$220.0K |
| YoY Change | -309.7% | -70.98% |
| Interest Expense | $4.000K | $30.00K |
| YoY Change | -93.33% | -50.82% |
| % of Operating Profit | 1.42% | |
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | $203.0K | -$143.0K |
| YoY Change | -21.32% | -81.81% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | 0.0% | |
| Net Earnings | -$42.00K | -$261.0K |
| YoY Change | -113.77% | -70.34% |
| Net Earnings / Revenue | -0.33% | -2.24% |
| Basic Earnings Per Share | -$0.01 | -$0.04 |
| Diluted Earnings Per Share | -$0.01 | -$0.04 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 6.986M | 6.987M |
| Diluted Shares Outstanding | 6.992M | 6.987M |
Balance Sheet
| Concept | 2019 Q4 | 2019 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $4.607M | $7.670M |
| YoY Change | 38.51% | 126.05% |
| Cash & Equivalents | $4.607M | $7.670M |
| Short-Term Investments | ||
| Other Short-Term Assets | $2.094M | $2.271M |
| YoY Change | -13.0% | -15.48% |
| Inventory | $2.056M | $1.989M |
| Prepaid Expenses | ||
| Receivables | $5.627M | $5.136M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $14.38M | $17.07M |
| YoY Change | 9.02% | 35.54% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $6.606M | $5.189M |
| YoY Change | -33.96% | -50.46% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $1.324M | |
| YoY Change | -8.12% | |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $385.0K | $762.0K |
| YoY Change | -52.59% | -15.52% |
| Total Long-Term Assets | $8.439M | $5.757M |
| YoY Change | -32.66% | -56.13% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $14.38M | $17.07M |
| Total Long-Term Assets | $8.439M | $5.757M |
| Total Assets | $22.82M | $22.82M |
| YoY Change | -11.28% | -11.24% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.647M | $1.555M |
| YoY Change | 7.93% | 8.59% |
| Accrued Expenses | $4.466M | $4.918M |
| YoY Change | 595.64% | 807.38% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $327.0K | $2.772M |
| YoY Change | 11.99% | 966.15% |
| Total Short-Term Liabilities | $6.440M | $9.245M |
| YoY Change | 13.42% | 71.27% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $110.0K | $115.0K |
| YoY Change | -96.09% | -95.8% |
| Other Long-Term Liabilities | $1.511M | $157.0K |
| YoY Change | 583.71% | -52.42% |
| Total Long-Term Liabilities | $1.621M | $1.756M |
| YoY Change | -57.51% | -56.19% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $6.440M | $9.245M |
| Total Long-Term Liabilities | $1.621M | $1.756M |
| Total Liabilities | $8.061M | $11.00M |
| YoY Change | -15.08% | 16.96% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $797.0K | |
| YoY Change | -57.22% | |
| Common Stock | $14.27M | |
| YoY Change | -2.43% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $14.76M | $14.81M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $22.82M | $25.81M |
| YoY Change | -11.28% | 0.38% |
Cashflow Statement
| Concept | 2019 Q4 | 2019 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$42.00K | -$261.0K |
| YoY Change | -113.77% | -70.34% |
| Depreciation, Depletion And Amortization | $350.0K | $335.0K |
| YoY Change | -49.2% | -19.86% |
| Cash From Operating Activities | -$348.0K | -$95.00K |
| YoY Change | 10.83% | -120.74% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $297.0K | $251.0K |
| YoY Change | 28.02% | -39.08% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $203.0K | $355.0K |
| YoY Change | -78.29% | 17650.0% |
| Cash From Investing Activities | -$94.00K | $104.0K |
| YoY Change | -113.49% | -122.91% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | $81.00K | |
| YoY Change | 20.9% | |
| Cash From Financing Activities | -2.621M | -81.00K |
| YoY Change | 482.44% | 20.9% |
| NET CHANGE | ||
| Cash From Operating Activities | -348.0K | -95.00K |
| Cash From Investing Activities | -94.00K | 104.0K |
| Cash From Financing Activities | -2.621M | -81.00K |
| Net Change In Cash | -3.063M | -72.00K |
| YoY Change | 4471.64% | 14.29% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$348.0K | -$95.00K |
| Capital Expenditures | $297.0K | $251.0K |
| Free Cash Flow | -$645.0K | -$346.0K |
| YoY Change | 18.13% | -852.17% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentNet | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtCurrent | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtNoncurrent | |
| CY2020Q4 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
913000 | |
| CY2020Q4 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
5000 | |
| CY2020Q4 | ssy |
Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
|
3417000 | |
| CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-340000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
13403000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
15043000 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-261000 | |
| CY2019Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
28000 | |
| CY2019Q4 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
6000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
14762000 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
1034000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-443000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
|
1000000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
|
548000 | ||
| us-gaap |
Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
|
40000 | ||
| us-gaap |
Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
|
558000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-960000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
10000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
4000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-17000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-2702000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
57000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-3135000 | ||
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7742000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11241000 | |
| ssy |
Interest Paid Received Net
InterestPaidReceivedNet
|
-1000 | ||
| ssy |
Interest Paid Received Net
InterestPaidReceivedNet
|
61000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
308000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
-43000 | ||
| us-gaap |
Transfer To Other Real Estate
TransferToOtherRealEstate
|
0 | ||
| us-gaap |
Transfer To Other Real Estate
TransferToOtherRealEstate
|
371000 | ||
| CY2020Q4 | ssy |
Operating Variable Lease Cost
OperatingVariableLeaseCost
|
0 | |
| CY2020Q4 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
120000 | |
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
9000 | |
| CY2020Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | |
| CY2020Q4 | ssy |
Finance Lease Cost
FinanceLeaseCost
|
11000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
|
57000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
35000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
72000 | |
| CY2019Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
150000 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
260000 | ||
| CY2020Q4 | ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
2000 | |
| CY2019Q4 | ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
2000 | |
| ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
4000 | ||
| CY2020Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
9000 | |
| CY2019Q4 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
8000 | |
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
17000 | ||
| CY2020Q4 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
682000 | |
| CY2019Q4 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
9000 | |
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
691000 | ||
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y10M24D | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y10M28D | |
| CY2019Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y9M7D | |
| ssy |
Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
|
691000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. – Business Operations </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s subsidiaries’ businesses are composed of two business segments:</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary which owns and operates Trace Regional Hospital and Floy Dyer Nursing Home (“Trace”), an 84 licensed-bed acute care hospital, located in Houston, Mississippi, which includes an 18-bed geriatric psychology unit (“GPU”), and a 66-bed nursing home. This facility focuses primarily on senior healthcare services.</font>   </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary, SunLink Health Systems Technology (“SHS Technology”), which provides information technology (IT) services to outside customers and to SunLink subsidiaries.</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Symbol;"><font style="font-size:10pt;font-family:'Times New Roman'">A</font><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font><font style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi.</font> </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.12%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="top" style="width:3.12%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">•</p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-family:Symbol;"><font style="font-size:10pt;font-family:'Times New Roman'">A</font><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font>subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</p></td></tr></table></div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment is composed of three operational areas which are conducted primarily in markets in southern Louisiana:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in Crowley, Louisiana; </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities; and,</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">•</font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</font></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">COVID-19 Pandemic</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance are recent, rapidly changing and at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:6.25%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2020, we began receiving allotments of COVID-19 vaccine and have begun to vaccinate patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate. Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:6.25%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Healthcare businesses, we have experienced material reductions in demand and net revenues due to the COVID-19 outbreak. There appears to be minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well in part due to the abrupt retirement of one physician in the quarter ended June 30, 2020 and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials. We continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at substantially reduced capacity. Until these referral sources are at full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the continuation of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID–19 pandemic and public and governmental responses to it negatively affected our last four fiscal quarters results.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period from April 1, 2020 to December 31, 2020, our <font style="color:#212529;">Healthcare and Pharmacy segments received $5,008 in general and targeted Provider Relief Fund (“PRF”) distributions. During the quarter ended June 30, 2020, we also received $3,234 in Paycheck Protection Programs (“PPP”) loans, administered by the SBA. Both the PRF and PPP funds are provided for under the CARES Act and we have received a total of $8,242 of such funding.</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for healthcare-related expenses and capital expenditures attributable to COVID-19, and “Lost Revenues” (as defined by HHS). Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. HHS has released “CARES Act Provider Relief Fund Frequently Asked Questions (“FAQ”) numerous times since April 3, 2020 through January 28, 2021 to clarify PRF requirements and has provided expansive examples of the reporting requirements in efforts to demonstrate amounts of the PRF received that may be considered to have been earned and which may be retained. The Company continues to review and analyze the FAQ. Of the $5,008 of PRF COVID-19 related distributions received during the period from April 1, 2020 through December 31, 2020, we are reporting $3,417 as other income in our consolidated statement of operations for our fiscal quarter ended December 31, 2020 related to COVID-19 related expenses and Lost Revenues. Our uses of PRF consisted of COVID-19 personal protective equipment, allowable capital expenditures and salary expenses for allowable patient care activities. The lost revenues were calculated as the reduction of patient care revenues in calendar 2020 compared to the calendar 2020 budget and actual patient care revenues of calendar 2019 in accordance with the latest guidance from HHS. The unrecognized amount of the PRF are recorded under the caption “Unearned CARES Act Funds” in our consolidated balance sheets. We will continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the distributions received may be impacted. We currently are uncertain if we will be able to utilize all of the PRF received under the currently existing interpretations by HHS and may have to return the unutilized portion of those funds, if any, in the future. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Forgiveness of PPP loans may be available if the loans were used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds subject to Federally-established terms and conditions. During July 2020, the allowable period for the use of PPP loan proceeds was amended to allow for a 24-week utilization period. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable use period. The forgiveness applications are to be reviewed by both the lender and the SBA and a loan forgiveness amount, if any, will be determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company has not yet applied for forgiveness of any of its PPP loans and recorded no income relating to the PPP loans through December 31, 2020.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided, including the requirements of PRF receipts and PPP loans. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that existing funds, cash generated from operations and additional sources of and access to financing from COVID-19 related government loans and grants will likely be adequate to satisfy our needs for working capital and capital expenditures in the next twelve months. However, if the COVID-19 pandemic continues for an extended period, we expect to experience significant losses and additional financial assistance will likely be required. <font style="color:#000000;"> </font></p> | ||
| CY2019Q4 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
|
-245000 | |
| ssy |
Share Repurchase Average Price Per Share Paid
ShareRepurchaseAveragePricePerSharePaid
|
1.17 | ||
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
|
-121000 | ||
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | ||
| CY2020Q4 | ssy |
Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
|
-5000 | |
| CY2019Q4 | ssy |
Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
|
13000 | |
| ssy |
Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
|
-2000 | ||
| ssy |
Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
|
37000 | ||
| CY2020Q4 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
|
-72000 | |
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
|
-363000 | ||
| CY2020Q4 | us-gaap |
Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
|
0 | |
| CY2019Q4 | us-gaap |
Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
|
0 | |
| us-gaap |
Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
|
0 | ||
| us-gaap |
Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
|
0 | ||
| CY2020Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
| CY2019Q4 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
0 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
28000 | ||
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | ||
| us-gaap |
Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
|
3814 | ||
| CY2020Q4 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
69000 | |
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
69000 | ||
| CY2019Q4 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
107000 | |
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
107000 | ||
| CY2020Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
7000 | |
| CY2019Q4 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
29000 | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
14000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
58000 | ||
| CY2020Q4 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
107000 | |
| CY2020Q2 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
124000 | |
| CY2020Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
1582000 | |
| CY2020Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
1401000 | |
| CY2020Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
|
1759000 | |
| CY2020Q2 | us-gaap |
Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
|
1957000 | |
| CY2020Q4 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
15000 | |
| us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
15000 | ||
| CY2020Q4 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
15000 | |
| us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
15000 | ||
| ssy |
Taxable Income Under Cares Act
TaxableIncomeUnderCARESAct
|
423000 | ||
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
7669000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2020Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
15248000 | |
| ssy |
Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
|
2023 through fiscal 2038 | ||
| CY2020Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
142000 | |
| CY2019Q4 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
143000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
260000 | ||
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
290000 | ||
| CY2020Q4 | ssy |
Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
|
-22000 | |
| CY2019Q4 | ssy |
Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
|
4000 | |
| ssy |
Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
|
29000 | ||
| ssy |
Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
|
15000 | ||
| CY2019Q4 | ssy |
Operating Variable Lease Cost
OperatingVariableLeaseCost
|
0 | |
| ssy |
Operating Variable Lease Cost
OperatingVariableLeaseCost
|
1000 | ||
| ssy |
Operating Variable Lease Cost
OperatingVariableLeaseCost
|
1000 | ||
| CY2019Q4 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
147000 | |
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
290000 | ||
| us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
306000 | ||
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
18000 | ||
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
18000 | ||
| CY2019Q4 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
2000 | |
| us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
4000 | ||
| us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
5000 | ||
| CY2019Q4 | ssy |
Finance Lease Cost
FinanceLeaseCost
|
11000 | |
| CY2020Q4 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
141000 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
289000 | ||
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
221000 | |
| CY2020Q4 | ssy |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
41000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1547000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
98000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1449000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
42000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
42000 | |
| ssy |
Finance Lease Cost
FinanceLeaseCost
|
22000 | ||
| ssy |
Finance Lease Cost
FinanceLeaseCost
|
23000 | ||
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
203000 | |
| CY2020Q2 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
203000 | |
| CY2020Q2 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentNet | |
| CY2020Q2 | us-gaap |
Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
|
43000 | |
| CY2020Q2 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
34000 | |
| CY2020Q2 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtCurrent | |
| CY2020Q2 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
90000 | |
| CY2020Q2 | us-gaap |
Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:LongTermDebtNoncurrent | |
| ssy |
Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
|
5000 | ||
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
16000 | ||
| us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
1448000 | ||
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y3M10D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0349 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0654 | |
| CY2019Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0553 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
498000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
294000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
251000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
242000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
36000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
0 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
0 | |
| CY2020Q4 | ssy |
Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
|
0 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
120000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
13000 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
107000 | |
| ssy |
Number Of Taxing Authorities
NumberOfTaxingAuthorities
|
2 | ||
| CY2019Q4 | us-gaap |
Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
|
359000 | |
| CY2020Q3 | us-gaap |
Assets
Assets
|
28522000 | |
| CY2020Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
405000 | |
| CY2019Q3 | us-gaap |
Assets
Assets
|
22823000 | |
| CY2019Q4 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
297000 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1000000 | ||
| CY2019Q4 | us-gaap |
Assets
Assets
|
22823000 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
548000 |
